Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-3.64%
Monthly Change
-4.50%
6 month change
-43.32%
Year Change
-48.29%
Previous Close
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volume
6
Markets
US Stock Market
Healthcare
TCRX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
—
Valuation ratios
Enterprise value
-53.51 M
-4.54 M
662.44 M
324.42 M
602.51 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-6.93
Price to sales ratio
—
3.04
17.8
120.9
212.92
Price to cash flow ratio
—
0.62
6.1
3.07
7.61
Price to book ratio
—
0.41
2.48
1.41
2.08
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.26
0.33
0.33
0.34
0.46
Return on equity %
0.3
0.67
0.59
0.53
0.77
Return on invested capital %
687.92
585.8
537.56
686.88
—
Gross margin %
100
100
100
100
400
Operating margin %
479.65
492.32
444
4 787.68
9 922.53
EBITDA margin %
—
—
—
—
—
Net margin %
479.49
489.26
423.86
4 527.66
9 580.2
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
30.19
Inventory turnover
—
—
—
—
—
Asset turnover
0.05
0.07
0.09
0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.41
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.69
Per share metrics
Operating cash flow per share
—
2.77
0.94
0.99
1.04
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
4.99
2.93
2.59
7.63
Net current asset value per share
—
5.16
2.96
2.61
7.73
Tangible book value per share
—
4.13
2.3
2.15
6.24
Working capital per share
—
4.44
2.51
2.29
6.72
Book value per share
—
4.13
2.3
2.15
6.24
News
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Tscan Therapeutics earnings beat by $0.06, revenue topped estimates
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates